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Computed tomography (CT) is presently a standard procedure for the detection of distant metastases in patients with oesophageal
or gastric cardia cancer. We aimed to determine the additional diagnostic value of alternative staging investigations. We included 569
oesophageal or gastric cardia cancer patients who had undergone CT neck/thorax/abdomen, ultrasound (US) abdomen, US neck,
endoscopic ultrasonography (EUS), and/or chest X-ray for staging. Sensitivity and specificity were first determined at an organ level
(results of investigations, i.e., CT, US abdomen, US neck, EUS, and chest X-ray, per organ), and then at a patient level (results for
combinations of investigations), considering that the detection of distant metastases is a contraindication to surgery. For this, we
compared three strategies for each organ: CT alone, CT plus another investigation if CT was negative for metastases (one-positive
scenario), and CT plus another investigation if CT was positive, but requiring that both were positive for a final positive result (two-
positive scenario). In addition, costs, life expectancy and quality adjusted life years (QALYs) were compared between different
diagnostic strategies. CT showed sensitivities for detecting metastases in celiac lymph nodes, liver and lung of 69, 73, and 90%,
respectively, which was higher than the sensitivities of US abdomen (44% for celiac lymph nodes and 65% for liver metastases), EUS
(38% for celiac lymph nodes), and chest X-ray (68% for lung metastases). In contrast, US neck showed a higher sensitivity for the
detection of malignant supraclavicular lymph nodes than CT (85 vs 28%). At a patient level, sensitivity for detecting distant metastases
was 66% and specificity was 95% if only CT was performed. A higher sensitivity (86%) was achieved when US neck was added to CT
(one-positive scenario), at the same specificity (95%). This strategy resulted in lower costs compared to CT only, at an almost similar
(quality adjusted) life expectancy. Slightly higher specificities (97–99%) were achieved if liver and/or lung metastases found on CT,
were confirmed by US abdomen or chest X-ray, respectively (two-positive scenario). These strategies had only slightly higher QALYs,
but substantially higher costs. The combination of CT neck/thorax/abdomen and US neck was most cost-effective for the detection
of metastases in patients with oesophageal or gastric cardia cancer, whereas the performance of CT only had a lower sensitivity for
metastases detection and higher costs. The role of EUS seems limited, which may be due to the low number of M1b celiac lymph
nodes detected in this series. It remains to be determined whether the application of positron emission tomography will further
increase sensitivities and specificities of metastases detection without jeopardising costs and QALYs.
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Patients with oesophageal or gastric cardia cancer have a dismal
prognosis, due to the presence of locally advanced cancer, lymph
node metastases or distant metastases at the time of presentation
in more than 50% of patients (Lightdale, 1999). Investigations that
can be used for staging oesophageal or gastric cardia cancer
include endoscopic ultrasonography (EUS) (Vickers and Alderson,
1998), computed tomography (CT) of neck, thorax, and abdomen
(Maerz et al, 1993), ultrasound (US) of the neck (Griffith et al,
2000) and abdomen (van Overhagen et al, 1992), chest X-ray (Stein
et al, 2001), bronchoscopy (Riedel et al, 1998), and
18F-fluoro-
2-deoxy-D-glucose positron emission tomography (FDG-PET)
(Leccisotti, 2006). The TNM stage of patients with oesophageal
or gastric cardia cancer is usually established by a combination of
these investigations. The TNM system is subdivided into the T
stage describing the extent of local invasion of the tumour through
the oesophageal wall, the N stage indicating whether metastases are
present in regional lymph nodes, and the M stage describing
whether distant metastases are present (Fleming et al. 1997).
The presence of distant metastases from oesophageal or gastric
cardia cancer is usually investigated by more than one modality. In
almost all patients, CT neck/thorax/abdomen is a standard
investigation. It is however not clear whether EUS, US neck and/or
abdomen, and chest X-ray are also necessary for assessing the
presence of distant metastases in these patients. In this study, we
aimed to determine the diagnostic value of EUS, US abdomen, US
neck, and chest X-ray in addition to CT in patients with oesophageal
or gastric cardia cancer. We evaluated these diagnostic procedures
both at an organ level and at a patient level for the detection of
metastases. The assumption was that the finding of distant
metastases in patients with oesophageal or gastric cardia cancer
would eliminate the option of a curative surgical treatment.
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sPATIENTS AND METHODS
Patients
We used a prospectively collected database with information on
1088 patients with oesophageal or gastric cardia cancer who were
diagnosed and treated between January 1994 and October 2003 at
the Erasmus MC – University Medical Center Rotterdam, The
Netherlands. Data that were collected included general patient
characteristics, results of staging investigations, treatment mod-
alities, and postoperative TNM stage. Additional information,
which was not present in the database but necessary for this study,
was obtained from the electronic hospital information system. We
assessed which preoperative investigations had been performed in
these 1088 patients.
In 906/1088 (83%) patients, oesophageal or gastric cardia cancer
was first diagnosed in a regional centre and, subsequently, these
patients were referred to our referral centre. Patients often
underwent preoperative staging investigations in these regional
centres; however, the results of these investigations were not
included in our analyses. In contrast, we identified 569 oesopha-
geal or gastric cardia cancer patients who had undergone CT neck/
thorax/abdomen and at least one other investigation, that is, US
abdomen, US neck and/or chest X-ray, in our centre (Figure 1).
Some of these patients had also undergone EUS (see below). The
reasons for performing these additional staging investigations were
in most cases a CT that was negative for the presence of metastases
or the suspicion of metastases on CT for which additional evidence
was required. FDG-PET was not performed in our centre during
the study period (1994–2003), and therefore, the additional value
of this modality could not be determined in this study.
Staging investigations
The organs to which oesophageal or gastric cardia cancers most
frequently metastasise, that is, liver, celiac lymph nodes, supra-
clavicular lymph nodes, and lung, were first evaluated separately
(‘organ level’). For this, we assessed whether both CT and US
abdomen, if indicated with fine-needle aspiration (FNA), should be
performed for the detection of liver metastases using the results of
335 patients who had undergone both investigations. In addition,
for the detection of malignant celiac lymph nodes, we analysed 143
patients who had undergone CT, US abdomen, and EUS, for
malignant supraclavicular lymph nodes, 546 patients who had
undergone CT and US neck, if indicated with FNA and for lung
metastases, 424 patients who had undergone CT and chest X-ray
(Figure 1). In case of a suspicious lesion, FNA was performed if the
result could change the treatment decision. If multiple suspicious
lesions were present, FNA of the most suspicious lesion was
performed. The results of the investigations were compared with
the gold standard, which was postoperative pathological TNM
stage, result of FNA, or a radiological finding in the relevant organ
with X6 months of follow-up. In patients in whom CT was
positive, however, US neck or abdomen negative, the latter was
repeated to determine whether the lesion could be found using the
CT information and to evaluate whether FNA could be performed.
In the current study, we did not use the results of this repeated
investigation, but used the result of the initial US neck or
abdomen. Nevertheless, if FNA could be performed, the FNA result
was used as gold standard.
For the interpretation of the results on a patient level, we
considered celiac lymph node metastases as regional (N1) if
the primary tumour was located in the gastric cardia, as stage
M1a if the tumour was located in the distal part of the oesophagus
and as stage M1b if the tumour was located in the mid or proximal
part of the oesophagus (Thompson, 1997). As oesophageal cancers
with M1a celiac lymph node metastases in many centres are
considered to be resectable (Hagen et al, 2001), only M1b celiac
lymph nodes were considered to be distant metastases in the part
of the study that was related to the interpretation on patient
level. In our data, only three patients had M1b celiac lymph
nodes. In addition, malignant supraclavicular lymph nodes
were considered as N1 if the tumour was located in the proximal
part of the oesophagus and as M1b if the tumour was located in the
mid or distal part of the oesophagus or in the gastric cardia
(Thompson, 1997).
Statistical analyses
Sensitivities, specificities, false-positive and false-negative results
of CT, US abdomen, EUS, US neck, and chest X-ray, alone or in
combination, for the detection of metastases in the various organs
were calculated. The combined results were calculated twice. First,
the result was considered positive for metastases if at least one of
two investigations that were performed for a particular organ
was positive, and negative if both investigations were negative
(one-positive scenario). This is a strategy that uses the possible
additional diagnostic information of the second investigation in
case of a negative CT. If the CT is positive, the result of another
investigation is irrelevant in this strategy, because the final result
will remain positive irrespective of the result of the other
investigation. Second, the result was considered positive if both
CT and another investigation were positive and negative if at least
one of the investigations was negative (two-positive scenario). This
is a strategy that uses additional diagnostic investigations to
confirm a positive CT finding. If the CT is negative, the
performance of another investigation is unnecessary using this
strategy, because the final result will remain negative irrespective
of the result of the other investigation. For celiac lymph nodes, the
number of false-positive and false-negative results was also
calculated for the combination of CT, US abdomen, and EUS.
In addition to analyses at the organ level, we considered analyses
at the patient level. Here, we assessed whether distant metastases
(M1b) were present in liver, lung, celiac lymph nodes, and
1088 patients 
569 patients with CT neck/thorax/abdomen and another  
investigation, that is US abdomen, US neck or chest X-ray 
335 patients with CT and US 
abdomen for malignant  
celiac lymph nodes and liver 
metastases
546 patients with CT and 
US neck for malignant  
supraclavicular lymph 
nodes
424 patients with CT and 
chest X-ray for lung 
metastases
Figure 1 Flow diagram of inclusion of patients.
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ssupraclavicular lymph nodes and, consequently, whether a curative
oesophageal resection should have been performed or not on the
basis of combinations of staging investigations using the data of
264 patients who had undergone all investigations. The assump-
tion was that an oesophageal resection should only be performed if
no distant metastases are detected. Similarly to the analyses at the
organ level, the strategies included CT, and the one-positive and
two-positive scenarios for the detection of metastases in liver,
celiac lymph nodes, supraclavicular lymph nodes, and lung. In
total, 81 different combinations of investigations were possible
(3 strategies for 4 organs). Sensitivities and specificities for the
detection of distant metastases at the patient level were calculated
for each combination.
Of the 569 patients, 305 patients had one or more missing
values, that is, these patients had not undergone all staging
investigations. An exploratory analysis was performed in which
missing values were imputed for these 305 patients by the
expectation maximisation (EM) method as implemented in SPSS
software (version 12, SPSS Inc., Chicago, IL, USA). This was
repeated five times to incorporate uncertainties in the imputation
process. Sensitivities and specificities for the detection of distant
metastases were calculated for each combination of investigations
using the five completed data sets (Rubin and Little, 2002; Schafer
and Graham, 2002).
We plotted sensitivity against one-specificity in a receiver
operating characteristic (ROC) curve for a visual comparison of
the accuracy of combinations of staging investigations using the
data of 264 patients who had undergone all investigations.
Sensitivity is the proportion of patients who are correctly
identified as having distant metastases (true positive results),
and one-specificity is the proportion of patients in whom the gold
standard is negative for distant metastases, and who are incorrectly
identified as positive by the staging investigation (false-positive
results). ROC curves were made for the detection of distant
metastases (M1b) with CT and the combination of CT and another
investigation (both the two-positive and one-positive scenarios) in
an organ, whereas in the other organs we only included the CT
result. For example, to assess whether both CT and US abdomen
should be performed to determine whether liver metastases were
present, we compared three different strategies: (1) combination of
CT and US abdomen in the two-positive scenario for the liver and
CT for the other organs; (2) combination of CT and US abdomen
in the one-positive scenario for the liver and CT for the other
organs; (3) CT for all organs.
The McNemar test was performed to determine whether the
differences between sensitivities of pairs of tests and specificities
of pairs of tests were statistically significant. We calculated
accuracy rates and 95% confidence intervals using exact methods
(Knottnerus, 2001). All P-values were based on two-sided tests
of significance. A P-valueo0.05 was considered as statistically
significant.
Cost-effectiveness analysis
Costs, life expectancies and quality-adjusted life years (QALYs)
were compared between the different combinations of investiga-
tions. As an extreme policy, we considered that all patients could
undergo surgery. Costs were estimated from data of the Erasmus
MC – University Medical Center Rotterdam, The Netherlands. The
extra costs of a resection over palliative treatment were estimated
to be approximately $50000, and the costs for the performance of
diagnostic investigations were for US: $100; for chest X-ray: $60;
and for CT: $750. These diagnostic work-up costs were negligible
compared to the costs of resection, and were therefore not taken
into account. Life expectancy and QALYs were taken from a
previous study (Wallace et al, 2002). Life expectancy was assumed
to be 2.41 and 1.00 year for local/regional disease with and without
resection, respectively, and 0.42 and 0.37 year for distant disease
with and without resection, respectively. QALYs were estimated to
be 1.45 and 0.70 for local/regional disease, and 0.17 and 0.19 for
distant disease, with and without resection, respectively. A cost-
effectiveness plane was constructed in which the differences in
costs between strategies (D costs) were plotted against the
differences in QALY (D QALY). Costs were expressed per $1000
(k$) for easier interpretation.
RESULTS
In Table 1, patient and tumour characteristics are shown for all 569
patients who had undergone both CT neck/thorax/abdomen and at
least one other investigation, that is, US abdomen, US neck and/or
chest X-ray, for the 264 patients who had undergone all
investigations and for the 305 patients who had undergone some
diagnostic investigations. w
2 testing revealed that the differences
between the patients with all (n¼264) or some (n¼305)
diagnostic investigations were statistically not significant.
Organ level
In Table 2, the gold standard diagnoses are shown per organ.
Positive gold standard diagnoses were confirmed by FNA or
resection in the majority of cases (92/135, 68%), whereas such
confirmation could not be used in the remaining cases. A reason
for this was that several patients had two or more suspicious
lesions and FNA had already been performed for one of these
lesions, which confirmed the presence of a distant metastasis.
FNA of the other suspicious lesions was therefore not indicated in
these patients.
Sensitivity for the detection of liver metastases was higher for
CT than for US abdomen, but this was statistically not significant
(73 vs 65%, P¼0.63; Table 3). Sensitivity for celiac lymph node
metastases was higher for CT than for US abdomen (69 vs 44%,
P¼0.08) and for EUS (38%, P¼0.03). Sensitivity for supraclavi-
cular lymph node metastases was higher for US neck than for CT
(85 vs 28%, Po0.001). Sensitivity for lung metastases was slightly
higher for CT than for chest X-ray, but this was statistically not
significant (90 vs 68%, P¼0.29).
Accuracies for combinations of staging investigations all
exceeded 80% (Table 3). If only CT was performed for liver
metastases, the number of false-positive results was 10 and the
number of false-negative results was 7. The addition of US
abdomen (one-positive scenario) resulted in a decline in the
number of false-negative results to 6, with also 10 false-positive
results. For celiac lymph nodes, the combination of CT plus US
abdomen (one-positive scenario) resulted in fewer false-negative
results in comparison with the performance of CT alone (6 vs 10).
If only CT was performed for supraclavicular lymph nodes, the
number of false-negative results was 42. With US neck or the
combination of CT and US neck (one-positive scenario) fewer
false-negative results were obtained (9 and 8, respectively). Overall,
the numbers of false-positive results were higher than the number
of false-negative results for combinations of CT with another
investigation in the one-positive scenarios. In contrast, the number
of false-negative results was higher in the two-positive scenarios
(Table 3).
Patient level
On the organ level, the results of EUS for the detection of
malignant celiac lymph nodes were inferior than for CT and US
abdomen. For that reason, EUS was considered to be less relevant
for the detection of distant metastases, and was not included in the
part of the analyses concerning patient level.
In the ROC curve, sensitivity and specificity of CT and the
combinations of CT and US abdomen (two-positive and one-positive
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sscenario) were more or less equal for liver metastases (Figure 2A),
which was in line with the results at the organ level. Adding US
abdomen (two-positive and one-positive scenario) to CT did not
result in a difference in sensitivity and specificity for malignant
celiac lymph nodes (Figure 2B). For malignant supraclavicular
lymph nodes, the combination of CT and US neck (one-positive
scenario) resulted in a better overall sensitivity compared to CT
alone and the combination of CT and US neck (two-positive
scenario), whereas specificities were comparable (Figure 2C). For
lung metastases, sensitivities and specificities were roughly equal
across the strategies (Figure 2D).
The sensitivity for detecting distant metastases was 66% and
specificity was 95% if only CT was performed for all organs
(Table 4). Higher sensitivities and specificities could be obtained
by the addition of one or more other staging investigations. The
highest sensitivity, which could be obtained with 12 of the 81
different combinations of staging investigations, was 86%. For 6 of
these 12 combinations, the specificity was 94.4%, whereas for 6
other combinations the specificity was only slightly higher
(94.9%). The lowest number of investigations for a sensitivity of
86% and a specificity of 94.9% was the combination of CT plus US
neck for the detection of supraclavicular lymph node metastases
(one-positive scenario), and CT only for the detection of
metastases in celiac lymph nodes, liver, and lung. A slightly
higher specificity of 97% was achieved by the addition of US
abdomen for liver metastases, but only in the two-positive
scenario. When chest X-ray (two-positive scenario) for the
detection of lung metastases was added, the specificity further
increased to 99%. Sensitivity declined with increasing specificity,
meaning that more patients would have undergone a curative
treatment option in the presence of distant metastases (more false-
negative results). The addition of US abdomen for the detection of
malignant celiac lymph nodes did not result in better results;
however, only 3/264 patients had M1b celiac lymph nodes, whereas
49 other patients had M1a celiac lymph nodes that did not
preclude a resection.
The average results obtained from the data with imputation of
missing values (n¼569) were roughly equal compared to the
results obtained from the complete data of patients who had
undergone all staging investigations (n¼264 patients; Table 4).
If only CT would have been performed, costs were high and
QALYs were low compared to other combinations of investiga-
tions. Therefore, the performance of CT only was dominated by
other combinations of investigations. Costs were lowest for the
combination of CT and US neck for supraclavicular lymph node
metastases (one-positive scenario) and CT only for the other
organs (average costs per patient: 39.8k$; Table 5; Figure 3).
Table 2 Gold standards in 569 patients with oesophageal or gastric
cardia cancer undergoing preoperative investigations for the detection of
metastases
Gold standard
Organ FNA
Postoperative
stage
Radiological
finding with X6 months
of follow-up
Liver (n¼335)
Positive (n¼26) 15 0 11
Negative (n¼309) 22 8 279
Celiac lymph nodes
(n¼143)
Positive (n¼32) 6 15 11
Negative (n¼111) 3 74 34
Supraclavicular lymph
nodes (n¼546)
Positive (n¼58) 44 6 8
Negative (n¼488) 68 35 385
Lung (n¼424)
Positive (n¼19) 5 1 13
Negative (n¼405) 7 0 398
FNA, fine-needle aspiration.
Table 1 Patient and tumour characteristics of 569 patients who had undergone CT neck/thorax/abdomen and at least one other investigation, that is, US
abdomen, US neck, and/or chest X-ray, the subgroup of 264 patients who had undergone all these investigations and the subgroup of 305 patients who had
undergone CT neck/thorax/abdomen plus at least one other diagnostic investigation for oesophageal or gastric cardia cancer staging
Variable
n¼569 (all
patients)
n¼264 (CT+US
neck+US
abdomen+chest X-ray)
n¼305 (CT+X1
other investigation
Mean age±standard deviation
(years)
61.9±10.2 61.2±10.4 62.5±10.0
Sex (%)
Male 436 (77) 207 (78) 229 (75)
Female 133 (23) 57 (22) 76 (25)
Histology of tumour at biopsy (%)
Squamous cell carcinoma 227 (40) 116 (44) 111 (37)
Adenocarcinoma 304 (53) 132 (50) 172 (56)
Other 38 (7) 16 (6) 22 (7)
Location of tumour (%)
Cervical 5 (1) 4 (2) 1 (1)
Upper 1/3 thoracic 30 (5) 11 (4) 19 (6)
Central 1/3 thoracic 101 (18) 53 (20) 48 (16)
Lower 1/3 thoracic 219 (38) 96 (36) 123 (40)
Gastroesophageal junction 214 (38) 100 (38) 114 (37)
Distant metastases according to gold standard (%)
M0 473 (83) 214 (81) 259 (85)
M1 96 (17) 50 (19) 46 (15)
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Surgery is presently the only established curative treatment option
for patients with oesophageal or gastric cardia cancer. However,
surgery is invasive, with a substantial risk of morbidity and
mortality. Therefore, adequate staging is of outmost importance to
select patients without distant metastases for undergoing surgery.
In this study, we assessed which traditional staging investigations
should be performed in patients with oesophageal or gastric cardia
cancer to determine whether distant metastases were present and,
consequently, whether a curative treatment, that is, an oesophageal
resection, could be performed. Our findings demonstrated that the
performance of CT only was not sensitive enough for the detection
of distant metastases. The addition of US neck to CT for the
detection of supraclavicular lymph node metastases resulted in the
highest sensitivity. For a slightly higher specificity (less false
positives), US abdomen and chest X-ray could be added, but this
required that both CT and these investigations were positive for
metastases to define the result as positive (two-positive scenario).
A higher specificity would however result in a decline in sensitivity
and consequently in more resections in patients with distant
metastases. We recognise that the requirement of two staging
procedures being positive is not a common clinical strategy.
Nonetheless, another investigation, in addition to CT, is sometimes
already used to confirm the suspicion of metastases on CT.
The choice for the optimal combination of investigations
usually depends on the relative weight one is willing to accept
for the number of patients with a false-positive (no curative
treatment option in the absence of distant metastases) vs those
with a false-negative staging result (a curative treatment option in
the presence of distant metastases). We formally assessed this
balance of false-positive vs false-negative staging results in a cost-
effectiveness analysis. A combination of investigations with a high
sensitivity for detecting distant metastases, but a lower specificity,
would result in relatively low costs, but the average life expectancy
and average QALYs would also be relatively low (Table 5). This is
due to the substantially lower QALYs for patients with local/
regional disease who would not undergo a resection (false-positive
staging result) compared with patients with local/regional disease
undergoing a resection. A higher specificity was only achievable
with a lower sensitivity, resulting in more patients undergoing a
resection in the presence of distant metastases. This resulted in
higher QALYs, but also in substantially higher costs. In cost-
effectiveness analyses, a ratio of approximately 50k$ per QALY is
generally considered to be acceptable for a clinical strategy
compared to a reference strategy (Gold et al, 1996). The ratios of
the alternatives were all far above this threshold in the present
study (Table 5) and, therefore, no single combination of
investigations was more cost-effective than the combination CT
and US neck.
On the basis of the results on the organ level, we concluded that
the performance of US abdomen, US neck, and chest X-ray,
respectively, in combination with CT resulted in a higher accuracy
compared to the performance of CT only. The addition of EUS had
no additional value over the performance of CT plus US abdomen
for the detection of malignant celiac lymph nodes, and for that
reason, EUS was not included in the part of the analysis
concerning patient level. We recognise that the sensitivity of EUS
Table 3 Sensitivities and specificities of CT, US abdomen, EUS, US neck, and chest X-ray only and the number of false-positive and false-negative results
and the accuracy rates plus 95% confidence intervals for CT, US abdomen, EUS, US neck, and chest X-ray only and the combinations of CT and the other
investigations in patients with oesophageal or gastric cardia cancer
Sensitivity Specificity
False-positive:
false-negative
Accuracy
rate
95% confidence
interval
Liver (n¼335, 26 metastases)
CT 19/26 (73%) 299/309 (97%) 10:7 0.95 0.92–0.97
USa 17/26 (65%) 308/309 (99%) 1:9 0.97 0.95–0.99
CT+USa: 1 positive 10:6 0.95 0.92–0.97
CT+USa: 2 positive 1:10 0.97 0.94–0.98
Celiac lymph nodes (n¼143, 32 metastases)
CT 22/32 (69%) 102/111 (92%) 9:10 0.87 0.80–0.92
USa 14/32 (44%) 111/111 (100%) 0:18 0.87 0.81–0.92
EUS 12/32 (38%) 104/111 (94%) 7:20 0.81 0.74–0.87
CT+EUS: 1 positive 11:6 0.88 0.82–0.93
CT+EUS: 2 positive 5:24 0.80 0.72–0.86
CT+USa: 1 positive 9:6 0.90 0.83–0.94
CT+USa: 2 positive 0:22 0.85 0.78–0.90
CT+USa+EUS: X1 positive 11:5 0.89 0.82–0.93
CT+USa+EUS: X2 positive 5:13 0.87 0.81–0.92
CT+USa+EUS: 3 positive 0:30 0.79 0.71–0.85
Supraclavicular lymph nodes (n¼546, 58 metastases)
CT 16/58 (28%) 484/488 (99%) 4:42 0.92 0.89–0.94
USn 49/58 (85%) 484/488 (99%) 4:9 0.98 0.96–0.99
CT+USn: 1 positive 7:8 0.97 0.96–0.98
CT+USn: 2 positive 1:43 0.92 0.89–0.94
Lung (n¼424, 19 metastases)
CT 17/19 (90%) 399/405 (99%) 6:2 0.98 0.96–0.99
CXR 13/19 (68%) 404/405 (99%) 1:6 0.98 0.97–0.99
CT+ CXR: 1 positive 7:0 0.98 0.97–0.99
CT+ CXR: 2 positive 0:8 0.98 0.96–0.99
CT¼computed tomography; CXR¼chest X-ray; EUS¼endoscopic ultrasonography; USa¼ultrasound abdomen; USn¼ultrasound neck.
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sfor the detection of celiac lymph nodes was lower in our study
compared to the literature (38% vs 75–100%, respectively),
whereas specificity was comparable (94% vs 50–100%, respec-
tively) (Catalano et al, 1999; Eloubeidi et al, 2001; Vazquez-
Sequeiros et al, 2001; Parmar et al, 2002). An explanation for this is
probably that in patients who were diagnosed and staged in the
early years of this study, FNA was not performed during EUS. In
addition, dilation was often not performed in patients with a
stenotic tumour. The few studies that have reported on sensitivities
and specificities of EUS for the detection of celiac lymph node
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Figure 2 ROC curves for the detection of metastases with CT and the combination of CT and another investigation (one-positive and two-positive
scenario) in an organ, whereas for the other organs only the result of CT was included vs the gold standard, with (A) liver, (B) celiac lymph nodes, (C)
supraclavicular lymph nodes, and (D) lung. J, CT for all regions; W, combination of CT and another investigation for the investigated region, with a positive
result if at least one investigation is positive (one-positive), and CT for the other regions; &, combination of CT and another investigation for the
investigated region, with a positive result if both investigations are positive (two-positive), and CT for the other regions.
Table 4 Sensitivities and specificities for the detection of distant metastases with combinations of staging investigations in patients with oesophageal or
gastric cardia cancer who had undergone all investigations (n¼264) and the average sensitivity and specificity of the 5 completed data sets (n¼569)
n¼264 n¼569
Supraclavicular
lymph nodes
Celiac lymph
nodes Liver Lung Sensitivity (%) Specificity (%) Sensitivity (%) Specificity (%)
CT CT CT CT 66 (33/50) 95 (204/214) 68 (65/96) 96 (454/473)
a
+USn: 1 pos CT CT CT 86 (43/50) 95 (203/214) 84 (81/96) 96 (453/473)
b
+USn: 1 pos CT +USa: 2 pos CT 82 (41/50) 97 (208/214) 81 (78/96) 98 (463/473)
c
+USn: 1 pos CT +USa: 2 pos +CXR: 2 pos 78 (39/50) 99 (211/214) 74 (71/96) 99 (469/473)
d
CT¼computed tomography; CXR¼chest X-ray; USa¼ultrasound abdomen; USn¼ultrasound neck.
a569/569 values (100%) were present before imputation of missing
values.
b1115/1138 values (98%) were present before imputation of missing values.
c1450/1707 values (85%) were present before imputation of missing values.
d1874/2276
values (82%) were present before imputation of missing values.
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smetastases have mainly been performed in centres with a high
volume of EUS procedures and a higher level of expertise.
Recently, we demonstrated that results of EUS performed in a
centre where o50 EUS procedures per endoscopist per year are
performed compare unfavourably with those reported from high-
volume EUS centres (van Vliet et al, 2006b). Until 2003,
endoscopists in our centre performed less than 50 EUS procedures
per person per year. Since 2003, we changed this policy and
presently only two dedicated EUS endoscopists with considerable
annual experience (450 EUS procedures per year) perform these
procedures. The results for the detection of malignant celiac lymph
nodes obtained by these endoscopists in the period between
November 2003 and May 2006 were higher compared to the results
reported in the previous period, with a sensitivity of 62% and a
specificity of 92% (unpublished results). As the data used in the
present study were obtained in patients diagnosed before
November 2003, the additional value of EUS for the detection of
malignant celiac lymph nodes is likely to have been under-
estimated in the present study. We assessed whether better EUS
results would have changed the results of our study. Here, we used
the median sensitivity and specificity of EUS from the literature
(80 and 92%, respectively). In the data set of 264 patients who had
undergone CT neck/thorax/abdomen, US abdomen, US neck, and
chest X-ray, we included these reported results of EUS. This
showed, however, that EUS had only limited additional value for
the detection of distant metastases at the patient level. An
explanation for this could, however, be that only 3/264 (1%)
patients had M1b celiac lymph nodes according to the gold
standard, whereas 49 other patients had M1a celiac lymph nodes
that did not preclude resection. Two of the three patients with M1b
celiac lymph nodes had also supraclavicular lymph node
metastases that were detected by both CT and US neck, and these
patients would not have undergone a resection anyhow, irrespec-
tive of the finding of M1b celiac lymph nodes by EUS or another
investigation. In the present study, the role of EUS seems to be
limited for the detection of distant metastases, which may be
particularly due to the low number of M1b celiac lymph nodes.
Nevertheless, EUS is still a useful method to determine the extent
of tumour invasion through the oesophageal wall (T stage) and to
investigate whether regional lymph node metastases (N stage) are
present (Lightdale and Kulkarni, 2005).
There are some other limitations to our study. Patients included
in this study were a selection of patients diagnosed with
oesophageal or gastric cardia cancer. This study was performed
in a referral centre and not all patients in whom distant metastases
were detected in regional centres were referred to our centre. In
addition, only preoperative staging investigations that were
performed in our centre were included in this retrospective study,
as it is known that the diagnostic sensitivity for metastases
detection is higher for investigations made and evaluated in a
high-volume referral centre compared to low-volume regional
centres (van Vliet et al, 2006a). Furthermore, only patients who
had undergone CT neck/thorax/abdomen and one or more other
investigations, that is, US abdomen, US neck and/or chest X-ray, in
our centre were included. However, no statistically significant
differences were found within the whole group of patients
(n¼569), according to whether all or some investigations had
been performed.
Second, sensitivities and specificities of CT, US abdomen, US
neck, and chest X-ray (Table 3) were largely in line with the
literature (Thompson et al, 1983; Quint et al, 1985; Yoshinaka et al,
1985; Lehr et al, 1988; Watt et al, 1989; Van Overhagen et al, 1993;
Tachimori et al, 1994; Bonvalot et al, 1996; Chandawarkar et al,
1996; Catalano et al, 1999; Natsugoe et al, 1999; Reed et al, 1999;
Eloubeidi et al, 2001; Vazquez-Sequeiros et al, 2001; Parmar et al,
2002; Kneist et al, 2003). Nevertheless, in other centres, the optimal
Table 5 Costs, life expectancies, and quality adjusted life years (QALYs) for patients with oesophageal or gastric cardia cancer who had undergone all
staging investigations (n¼264)
Supraclavicular
lymph nodes
Celiac
lymph
nodes Liver Lung
Number of
patients with
operation (%)
Costs per
patient (k$)
Life expectancy
per patient
(year)
QALY per
patient
D Costs/D QALY
(k$ per QALY)
CT CT CT CT 221/264 (84) 41.9 1.973 1.178 Dominated
+USn: 1 pos CT CT CT 210/264 (80) 39.8 1.966 1.176 Reference
+USn: 1 pos CT +USa: 2 pos CT 217/264 (82) 41.1 1.993 1.190 94,7
+USn: 1 pos CT +USa: 2 pos +CXR: 222/264 (84) 42.0 2.010 1.198 113,3
Surgery in all patients 2 pos 264/264 (100) 50.0 2.033 1.204 365,3
CT¼computed tomography; CXR¼chest X-ray; pos¼positive scenario; USa¼ultrasound abdomen; Usn¼ultrasound neck.
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Figure 3 Marginal cost-effectiveness plane calculated in patients with oesophageal or gastric cardia cancer who had undergone all staging investigations
(n¼264) and using the five completed data sets (n¼569). The combination of CT and US neck for the detection of supraclavicular lymph node metastases
(one-positive scenario), and CT only for the detection of metastases in celiac lymph nodes, liver and lung was considered as reference strategy.
CT¼computed tomography; CXR¼chest X-ray; QALY, quality adjusted life year; USa¼ultrasound abdomen; USn¼ultrasound neck.
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sstrategy to stage patients with oesophageal or gastric cardia cancer
is not automatically the combination of CT and US neck, as
sensitivities and specificities of combinations of investigations
largely depend on the quality of the staging investigations in a
centre. This quality is determined by both experience of the
investigator and quality of the equipment.
Third, positron emission tomography (PET) scanning was not
used in the patients who were included in this retrospective
study. PET has been suggested to be potentially valuable for the
detection of distant metastases, especially modern PET-CT scans
(Rosenbaum et al, 2006). Therefore, further studies need to
determine the exact role of PET in the staging of oesophageal or
gastric cardia cancer.
Finally, the relatively low numbers of patients with metastases
may limit the interpretation of comparisons of sensitivities and
specificities. However, the conclusion on the optimal staging
strategy is quite robust, because detectable metastases in some
organs are relatively rare. Extra diagnostic evaluations can hence
not be very cost-effective, although no formal analysis of
uncertainty was performed (bootstrapping, or construction of
acceptability curves) (Willan and Briggs, 2006).
In conclusion, the combination of CT neck and US neck for the
detection of supraclavicular lymph node metastases and CT
thorax/abdomen for the detection of metastases in celiac lymph
nodes, liver, and lung is a cost-effective strategy for the detection
of distant metastases in patients with oesophageal or gastric cardia
cancer. US abdomen and chest X-ray have only limited additional
value in the detection of distant metastases in these patients. These
staging investigations should only be performed for specific
indications in patients with oesophageal or gastric cardia cancer,
as the treatment decision is not improved in most of the patients if
these investigations are added to the diagnostic work-up. The role
of EUS for the detection of distant metastases seems also be
limited, which may be particularly due to the low number of M1b
celiac lymph nodes in the present study.
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